Welcome!

News Feed Item

Fc Protein and Glycoengineered Antibodies Market

DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from both large and small pharmaceutical companies. Developed through introduction of modifications in monoclonal antibodies, the aim is to develop antibodies with improved efficacy.

Research done in the last decade to develop engineered antibodies has yielded a rich knowledge base on how to develop and market these next generation antibodies. These therapeutic antibodies seem to be more promising, with improved properties when compared to their ancestors. There are several molecules in phase II / III clinical trials and a few waiting for approvals. In addition, a large number of molecules are also in pre-clinical trials and are expected to progress through various stages of drug development over the next ten years.

The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are:

  • Fc Glycoengineering (referred to as Glycoengineering' in the report)
  • Fc Protein engineering

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. INTRODUCTION

3. ENGINEERED ANTIBODIES: OVERVIEW AND BACKGROUND

4. GLYCOENGINEERED ANTIBODIES MARKET, 2012 - 2023

5. Fc PROTEIN ENGINEERED ANTIBODIES MARKET, 2013 - 2023

6. TECHNOLOGICAL PLATFORMS FOR ENGINEERED ANTIBODIES

7. PROFILES OF LEADING COMPANIES

8. SWOT ANALYSIS

9. CONCLUSIONS

10. APPENDIX 1: TABLES

11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS


Companies Mentioned:

  • ABN AMRO Capital
  • AVID Bioservices
  • Absolute Antibody
  • Accurus Biosciences
  • Affitech A/S
  • Allos Therapeutics
  • Amgen
  • Andromeda Biotech
  • Applied Molecular Evolution (AME)
  • Astra Zeneca
  • BioMedinvest
  • BioWa
  • BioXcellence
  • BioXpress Therapeutics
  • Bioceros
  • Biocon
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • CSL
  • Celltrion
  • Centocor Ortho Biotech
  • Cephalon
  • ChemoCentryx
  • Chugai Pharmaceuticals
  • Deutsche Venture Capital
  • Diamyd Medical
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Eureka Therapeutics
  • Five Prime Therapeutics
  • GSK
  • Genentech
  • Gilde Investment Management
  • Global Life Science Ventures
  • Glycart
  • Glycode
  • Glycotope
  • Green Cross Corporation
  • Greenovation
  • Halozyme Therapeutics
  • Hanwha Chemical
  • Human Genome Sciences
  • ISU Abxis
  • Ildong Pharmaceuticals
  • ImmunGene
  • Inhibrx
  • InvivoGen
  • KaloBios
  • Kyowa Hakko Kirin
  • Laboratoire français du Fractionnement et des Biotechnologies (LFB)
  • Life Science Pharmaceuticals
  • Lonza
  • MacroGenics
  • MedImmune
  • Meiji Seika Pharma
  • Mentrik Biotech
  • Merck-GlycoFi
  • Micromet
  • MilleGen
  • Minapharm Pharmaceuticals
  • Morphosys
  • Mylan
  • NKT Therapeutics
  • Nippon Kayaku
  • Nippon Shinyaku
  • Novartis
  • Novartis Venture Fund
  • Ortho-McNeil Janssen Pharmaceutical
  • PDL Biopharma
  • Pfizer
  • Pikamab
  • Pinnacle Oncology Hematology
  • PlantForm Corporation
  • ProStrakan
  • Quester Capital Management
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Schnell Biopharma
  • Seattle Genetics
  • Servier
  • Shanghai CP Guojian
  • SiaMedExpress
  • Sorrento Therapeutics
  • Synthon-Biolex
  • TG Therapeutics
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
  • Trubion
  • Vivalis
  • Watson Pharmaceuticals
  • WuXi AppTec
  • Xencor
  • Zymeworks
  • arGEN-X
  • biOasis Technologies
  • rEVO Biologic

For more information visit http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors!
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
JETRO showcased Japan Digital Transformation Pavilion at SYS-CON's 21st International Cloud Expo® at the Santa Clara Convention Center in Santa Clara, CA. The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.